TRACON Pharmaceuticals Inc News Releases http://ir.traconpharma.com/ TRACON Pharmaceuticals Inc News Releases en TRACON Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference http://ir.traconpharma.com/news-releases/news-release-details/tracon-pharmaceuticals-present-jefferies-2019-healthcare SAN DIEGO , May 30, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and through our license to Santen Pharmaceutical Co. Ltd. Thu, 30 May 2019 08:05:00 -0400 TRACON Pharmaceuticals Inc News Releases 9716 TRACON Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update http://ir.traconpharma.com/news-releases/news-release-details/tracon-pharmaceuticals-reports-first-quarter-2019-financial SAN DIEGO , May 14, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and through our license to Santen Pharmaceutical Co. Ltd. Tue, 14 May 2019 16:03:00 -0400 TRACON Pharmaceuticals Inc News Releases 9691 TRACON to Report First Quarter 2019 Company Highlights and Financial Results on May 14, 2019 http://ir.traconpharma.com/news-releases/news-release-details/tracon-report-first-quarter-2019-company-highlights-and SAN DIEGO , May 07, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and, through our license to Santen Pharmaceutical Co. Ltd. Tue, 07 May 2019 16:05:00 -0400 TRACON Pharmaceuticals Inc News Releases 9681 TRACON Pharmaceuticals Announces Termination of Phase 3 TAPPAS Trial Based on the Recommendation of the Independent Data Monitoring Committee http://ir.traconpharma.com/news-releases/news-release-details/tracon-pharmaceuticals-announces-termination-phase-3-tappas Company to Host Investor Conference Call Today at 8:30 a.m. EDT / 5:30 a.m. PDT SAN DIEGO , April 12, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer Fri, 12 Apr 2019 06:55:00 -0400 TRACON Pharmaceuticals Inc News Releases 9651 TRACON Pharmaceuticals Announces TRC105, TRC253 and TRC102 Data Presentations at Upcoming AACR Annual Meeting http://ir.traconpharma.com/news-releases/news-release-details/tracon-pharmaceuticals-announces-trc105-trc253-and-trc102-data SAN DIEGO , March 27, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and, through our license to Santen Pharmaceutical Co. Ltd. Wed, 27 Mar 2019 08:05:00 -0400 TRACON Pharmaceuticals Inc News Releases 9641 TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update http://ir.traconpharma.com/news-releases/news-release-details/tracon-pharmaceuticals-reports-fourth-quarter-and-year-end-2018 SAN DIEGO , Feb. 28, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and through our license to Santen Pharmaceutical Co. Ltd. Thu, 28 Feb 2019 16:02:00 -0500 TRACON Pharmaceuticals Inc News Releases 9611 TRACON to Report Fourth Quarter and Full Year 2018 Company Highlights and Financial Results on February 28, 2019 http://ir.traconpharma.com/news-releases/news-release-details/tracon-report-fourth-quarter-and-full-year-2018-company SAN DIEGO , Feb. 21, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that it will report its Thu, 21 Feb 2019 16:03:00 -0500 TRACON Pharmaceuticals Inc News Releases 9606 TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma http://ir.traconpharma.com/news-releases/news-release-details/tracon-pharmaceuticals-announces-positive-data-ongoing-phase-0 Three Confirmed Partial Responses (20%) by RECIST and > 50% Reductions of Alpha Fetoprotein in Half of Patients Treated to Date with Combination of TRC105 and Nexavar®   Data Presented at ASCO 2019 Gastrointestinal Cancers Symposium SAN DIEGO , Jan. 22, 2019 (GLOBE NEWSWIRE) -- TRACON Tue, 22 Jan 2019 08:30:00 -0500 TRACON Pharmaceuticals Inc News Releases 9561 I-Mab Biopharma Receives U.S. FDA IND Clearance for Proprietary CD73 Antibody TJD5 http://ir.traconpharma.com/news-releases/news-release-details/i-mab-biopharma-receives-us-fda-ind-clearance-proprietary-cd73 Fri, 18 Jan 2019 11:00:00 -0500 TRACON Pharmaceuticals Inc News Releases 9576 TRACON Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo® for Treatment of Non-Small Cell Lung Cancer http://ir.traconpharma.com/news-releases/news-release-details/tracon-pharmaceuticals-presents-positive-top-line-clinical-data SAN DIEGO , Dec. 26, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced Wed, 26 Dec 2018 16:05:00 -0500 TRACON Pharmaceuticals Inc News Releases 9551